News >

Crizotinib Demonstrates Durable Activity in ROS1+ NSCLC

Jason Harris
Published: Friday, Apr 06, 2018

Yi Long Wu, MD
Yi Long Wu, MD
Crizotinib (Xalkori) induced a nearly 72% overall response rate and a median progression-free survival of almost 16 months in a single-arm phase II trial of 127 patients with ROS1-positive advanced non–small cell lung cancer (NSCLC).

Overall, 10 patients (7.9%) experienced a grade 5 AE, though none were related to crizotinib.
Wu YL, Yang JCH, Kim DW, et al. Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non–small-cell lung cancer [published online March 29, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.75.5587.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x